From infectious disease to oncology: translating a novel glycan target into a ‘pan-cancer’ ADC
Bioconjugate Insights · 24.03.2026 · 1 (2) · 75–79
DOI: 10.18609/bci.2026.011 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioconjugate Insights, online erschienen am 24.03.2026. Verfasst von Ali Salanti. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
“We recently obtained the first data ... which demonstrates that the antibody reaches the tumors to a significant extent with very limited off-target binding.”Lauren Coyle, Editor, Bioconjugate Insights, speaks with Ali Salanti, Professor, University of Copenhagen, and CEO, Var2 Pharma, about the development of a new monovalent ADC with broad anti-tumor activity – from a serendipitous discovery to preparing for clinical trials.
Zitieren
APA
Salanti, A. (2026). From infectious disease to oncology: translating a novel glycan target into a ‘pan-cancer’ ADC. Bioconjugate Insights, 1(2), 75–79. https://doi.org/10.18609/bci.2026.011
Vancouver
Salanti A. From infectious disease to oncology: translating a novel glycan target into a ‘pan-cancer’ ADC. Bioconjugate Insights. 2026;1(2):75–79. doi:10.18609/bci.2026.011
BibTeX
@article{Salanti2026,
author = {Salanti, Ali},
title = {From infectious disease to oncology: translating a novel glycan target into a ‘pan-cancer’ ADC},
journal = {Bioconjugate Insights},
year = {2026},
volume = {1},
number = {2},
pages = {75–79},
doi = {10.18609/bci.2026.011}
}
EUVIMED